ABVC $1.11 (-16.29%) Quote details

Establish your trading edge with a set of smart tools for serious trades. Upgrade Account
stock

ABVC Biopharma Inc

NASDAQ | ABVC

1.10

USD

-0.215 (-16.29%)

AT CLOSE (AS OF Apr 2, 2025)

$26M

MARKET CAP

-

P/E Ratio

-0.81

EPS

$1.7

52 Week High

$0.4

52 Week Low

LIFE SCIENCES

Sector

ABVC Chart

1D
Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Icon For Time-schedule

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More
Icon For Search

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More
Icon For Clipboard-list

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More

ABVC Technicals

Tags:

ABVC Earnings

Earnings Performance

ABVC Financials

yearly Balance Sheet (As of Sep 30, 2024)

Field Value (USD)
Total Assets $14M
Total Current Assets $2.1M
Cash And Cash Equivalents At Carrying Value $137K
Cash And Short Term Investments $208K
Inventory -
Current Net Receivables $1.5K
Total Non Current Assets $11M
Property Plant Equipment $7.9M
Accumulated Depreciation Amortization Ppe $3.3M
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments $297K
Long Term Investments $2.3M
Short Term Investments $71K
Other Current Assets -
Other Non Current Assets -
Total Liabilities $6.5M
Total Current Liabilities $6.3M
Current Accounts Payable -
Deferred Revenue $180K
Current Debt $866K
Short Term Debt $866K
Total Non Current Liabilities $142K
Capital Lease Obligations -
Long Term Debt $1M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.9M
Other Current Liabilities $419K
Other Non Current Liabilities -
Total Shareholder Equity $8.4M
Treasury Stock $8.9M
Retained Earnings -
Common Stock $13K
Common Stock Shares Outstanding $13M

yearly Cash Flow (As of Dec 31, 2023)

Field Value (USD)
Operating Cashflow -$4.2M
Payments For Operating Activities $61K
Proceeds From Operating Activities -
Change In Operating Liabilities $8.3K
Change In Operating Assets -$8.7K
Depreciation Depletion And Amortization $29K
Capital Expenditures $21K
Change In Receivables $93K
Change In Inventory $69K
Profit Loss -$11M
Cashflow From Investment -$360K
Cashflow From Financing $3.9M
Proceeds From Repayments Of Short Term Debt -$1M
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock $1.1M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net $1.5M
Proceeds From Issuance Of Preferred Stock $2.4M
Proceeds From Repurchase Of Equity $3.5M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$11M

ABVC Profile

ABVC Biopharma Inc Profile

Sector: LIFE SCIENCES

Industry: PHARMACEUTICAL PREPARATIONS

American BriVision (Holding) Corporation, a clinical-stage biopharmaceutical company, develops drugs and medical devices to meet unmet medical needs in the United States.

Discover more tools and features to empower your trading
Explore Features

Quotes and other market data may be delayed by 15 minutes or more. Financial data is provided by financial exchanges and other content providers and may be delayed as specified by financial exchanges or other data providers. AfterPullback does not verify any data and disclaims any obligation to do so. The information contained on this website is not intended as, and shall not be understood as, financial advice. The website does not operated by attorney, accountant or financial advisor and the information contained on this website is not a substitute for financial advice from a professional who is aware of the facts and circumstances of your individual situation. Nothing available on or through this website should be understood as a recommendation that you should not consult with a financial professional to address your particular information.